Biagio Ricciuti: How adaptive mechanisms and increased GTP loading confer resistance to KRAS G12C OFF
Biagio Ricciuti shared on X:
“Our in Nature Communications our collaborative effort showing how adaptive mechanisms and increased GTP loading confer resistance to KRAS G12C OFF.
Selective inhibitor RMC-4998 targeting GTP-bound (ON) KRAS can overcome resistance.
With Ambrogio Lab.”
Source: Biagio Ricciuti/X
Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School.
His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade.
Authors: Marie-Julie Nokin, Alessia Mira, Enrico Patrucco, Biagio Ricciuti, Sophie Cousin, Isabelle Soubeyran, Sonia San José, Serena Peirone, Livia Caizzi, Sandra Vietti Michelina, Aurelien Bourdon, Xinan Wang, Daniel Alvarez-Villanueva, María Martínez-Iniesta, August Vidal, Telmo Rodrigues, Carmen García-Macías, Mark M. Awad, Ernest Nadal, Alberto Villanueva, Antoine Italiano, Matteo Cereda, David Santamaría and Chiara Ambrogio.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023